KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Non-Current Liabilities for 17 consecutive years, with $4.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 10.08% year-over-year to $4.0 billion; the TTM value through Mar 2026 reached $4.0 billion, up 10.08%, while the annual FY2025 figure was $4.2 billion, 10.31% up from the prior year.
  • Total Non-Current Liabilities hit $4.0 billion in Q1 2026 for Alnylam Pharmaceuticals, down from $4.2 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $4.2 billion in Q3 2025 and bottomed at $2.9 billion in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities rose 29.54% in 2022 and then dropped 1.28% in 2025.
  • Alnylam Pharmaceuticals' Total Non-Current Liabilities stood at $3.5 billion in 2022, then rose by 7.16% to $3.7 billion in 2023, then grew by 1.01% to $3.8 billion in 2024, then rose by 10.31% to $4.2 billion in 2025, then dropped by 2.95% to $4.0 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $4.0 billion, $4.2 billion, and $4.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.